AskBio to Present New AAV Manufacturing Data in Hamburg
The company will detail five research projects aimed at improving viral vector reproducibility at the 33rd ESGCT congress.
Updated on Oct. 24, 2026 in Biotech
AskBio is scheduled to present five posters regarding gene therapy manufacturing technology at the 33rd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT). These research-stage presentations, occurring in Hamburg, Germany, detail advances in rAAV production platforms.
Why it matters
The presentations address critical challenges in gene therapy scalability by focusing on making viral vector production more reproducible and robust. These manufacturing refinements are essential for transitioning gene therapies from clinical research to widespread clinical application.
Four of the five presentations focus on rAAV (recombinant adeno-associated virus) manufacturing technologies. These findings aim to optimize production processes for viral vectors, the delivery vehicles used to transport genetic material into target cells.
The players
AskBio
A gene therapy company and Bayer AG subsidiary focused on AAV-based platform development and vector production.
Bayer AG
A global life sciences company with a core focus on pharmaceutical innovation and the parent organization of AskBio.
Viralgen Vector Core S.L.U.
A subsidiary of AskBio established in 2017 that specializes in the manufacturing of clinical-grade rAAV vectors.
The details
The research sessions cover advances in the platforms used to create AAV vectors, which are modified, harmless viruses used as delivery vehicles for gene therapies. By focusing on manufacturing technology, AskBio intends to standardize the production of these vectors, which historically suffer from variability in yield and purity. These efforts aim to improve the reproducibility and measurability of gene therapy batches during large-scale manufacturing.
Timeline
October 27-30, 2026: The ESGCT 33rd Annual Congress convenes in Hamburg, Germany.
October 28, 2026: The first round of poster session presentations occurs.
October 29, 2026: The second round of poster session presentations occurs.
The Tech Race
As the field of gene therapy matures, the race to optimize AAV vector manufacturing has become a central bottleneck for commercial viability. This research follows a long-term industry trend toward automating and standardizing viral vector production to match pharmaceutical-grade quality requirements.
These manufacturing advances serve as foundational research for future treatments and are not currently available as clinical products. The company projects that these platform improvements could eventually support the treatment of more than 35 million patients worldwide.
The takeaway
The scalability of gene therapy depends entirely on the ability to manufacture viral vectors with consistency and high yield. Industry observers should watch for the performance benchmarks shared during these sessions to determine if AskBio’s methods yield statistically significant improvements over existing production standards.
Further reading
For broader trends in production technology, explore the latest developments in Biotech.
Source note: This article includes information reported by Pharmabiz.
